A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors
Johann S. de Bono(Royal Marsden NHS Foundation Trust), Elisabeth G.E. de Vries(University Medical Center Groningen)
Cited by 3
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2020|760
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
|British Journal of Cancer|2007|231
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
|CA A Cancer Journal for Clinicians|2011|209